Endostatin
- Generic Name
- Endostatin
- Drug Type
- Biotech
- CAS Number
- 187888-07-9
- Unique Ingredient Identifier
- 67RHC0R671
- Indication
Investigated for use/treatment in cancer/tumors (unspecified), macular degeneration, and diabetic retinopathy.
Anlotinib Maintenance Therapy Shows Promise in Extensive-Stage Small Cell Lung Cancer
• A retrospective study indicates that anlotinib maintenance therapy, particularly when combined with immunotherapy, significantly improves progression-free survival (PFS) and overall survival (OS) in ES-SCLC patients.
• The median PFS was 7.2 months for all patients, and the median OS reached 17.6 months, highlighting the potential of anlotinib in prolonging survival in this aggressive cancer.
• Combining anlotinib with immunotherapy resulted in a median PFS of 8.2 months and a median OS of 20.1 months, demonstrating a statistically significant improvement compared to anlotinib with chemotherapy.
• The study confirms that anlotinib-related adverse events are manageable, with no unexpected toxicities or treatment-related deaths, supporting its safety profile in ES-SCLC maintenance therapy.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath